Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778592 | 0.88 | L3MBTL1 (0.56) | HTR6CYP2C19L3MBTL1POLBPKM | |
| SCHEMBL1672537 | 0.82 | CYP2C19 (0.58) | HTR6CYP2C19METL3MBTL1MEN1 | |
| SCHEMBL31668610 | 0.81 | HTR6 (0.47) | HTR6CYP2C19METL3MBTL1POLB | |
| SCHEMBL16040211 | 0.81 | HTR6 (0.49) | HTR6CYP2C19 | |
| SCHEMBL17535066 | 0.81 | HTR6 (0.54) | HTR6CYP2C19METL3MBTL1POLB | |
| SCHEMBL31668616 | 0.80 | HTR6 (0.46) | HTR6CYP2C19L3MBTL1POLBMEN1 | |
| SCHEMBL13014082 | 0.79 | CYP2C19 (0.58) | HTR6CYP2C19METL3MBTL1MEN1 | |
| SCHEMBL1683430 | 0.79 | CYP2C19 (0.58) | HTR6CYP2C19METL3MBTL1MEN1 | |
| SCHEMBL17628860 | 0.79 | CYP2C19 (0.58) | HTR6CYP2C19METL3MBTL1MEN1 | |
| SCHEMBL414843 | 0.79 | CYP2C19 (0.58) | HTR6CYP2C19METL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716493-B2 | Multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2066324-B1 | CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON INC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | CEPHALON, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | CEPHALON, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2066324-A2 | CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON, INC. (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2007149451-A2 | CYCLOALKANOPYRROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | MLKL, PARP3, PARP1 | HTR6 1439/4885CYP2C19 1885/4885SLC40A1 4764/4885 |
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | HTR6 3348/4885CYP2C19 1492/4885SLC40A1 4654/4885 |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | MLKL, PARP3, PARP1 | HTR6 1439/4885CYP2C19 1885/4885SLC40A1 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.